Michael B. Dwinell

This study identifies oncogenic KRAS as a driver of NF-κB-mediated CCL20 chemokine expression in pancreatic ductal adenocarcinoma and shows that targeting CCL20-CCR6 signaling can modulate immune cell recruitment.

This study shows that CXCL12-LD, a dimeric variant of the chemokine, reduces chemotaxis in AML cells by altering receptor signaling and internalization, suggesting potential for improved CXCR4 targeting.

This paper identifies gait speed as a more reliable biomarker of cancer-associated cachexia decline and recovery compared to grip strength, using both animal models and human patient data.